Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial.

@article{Morgan1994SupplementationWF,
  title={Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial.},
  author={S L Morgan and Joseph E. Baggott and W. Harry Vaughn and J S Austin and T A Veitch and J Y Lee and W J Koopman and Carlos L Krumdieck and Graciela S Alarc{\'o}n},
  journal={Annals of internal medicine},
  year={1994},
  volume={121 11},
  pages={833-41}
}
The folic acid antagonist methotrexate (n-10-methyl-aminopterin) is useful in low doses (2.5 to 20 mg/wk) for treating chronic inflammatory diseases [1-7]. Many trials have established the efficacy of methotrexate in rheumatoid arthritis [7-13]. Compared with other disease-modifying drugs, methotrexate has the highest probability of drug continuation at 10 years. Dose response-related toxic effects have been reported in 30% to 90% of patients given methotrexate [13]. Toxic effects include… CONTINUE READING
84 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 84 extracted citations

Similar Papers

Loading similar papers…